Isomorphic Labs has secured $5 billion in a Series C funding round. This investment follows a $2.1 billion Series B round completed six months ago. The company, founded by Demis Hassabis as a spin-out from Google DeepMind, focuses on using artificial intelligence for drug discovery.

The funding round was co-led by Sequoia and Greenoaks. Other participants include Andreessen Horowitz, Thrive Capital, Alphabet, GV, CapitalG, Temasek, and the Sovereign AI fund. The company utilizes software developed by DeepMind, including the AlphaFold model, to research treatments for cancer and immune disorders.

The capital will be used to scale the proprietary drug design engine, IsoDDE, and to support clinical development infrastructure. Isomorphic Labs plans to advance its drug candidates into clinical trials and expand its research into new areas of biology using advanced AI models.

The company is also establishing a partner ecosystem to improve the understanding of disease biology. According to CEO Demis Hassabis, the funding will accelerate the development of foundational biology models and drive the company's first therapeutic programs toward clinical trials.